291 related articles for article (PubMed ID: 9616206)
21. Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells.
Costantino CM; Ploegh HL; Hafler DA
J Immunol; 2009 Jul; 183(2):945-52. PubMed ID: 19553543
[TBL] [Abstract][Full Text] [Related]
22. Pepstatin A-sensitive aspartic proteases in lysosome are involved in degradation of the invariant chain and antigen-processing in antigen presenting cells of mice infected with Leishmania major.
Zhang T; Maekawa Y; Yasutomo K; Ishikawa H; Fawzy Nashed B; Dainichi T; Hisaeda H; Sakai T; Kasai M; Mizuochi T; Asao T; Katunuma N; Himeno K
Biochem Biophys Res Commun; 2000 Sep; 276(2):693-701. PubMed ID: 11027533
[TBL] [Abstract][Full Text] [Related]
23. Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue.
Zavasnik-Bergant V; Sekirnik A; Golouh R; Turk V; Kos J
Biol Chem; 2001 May; 382(5):799-804. PubMed ID: 11517933
[TBL] [Abstract][Full Text] [Related]
24. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells.
Pierre P; Mellman I
Cell; 1998 Jun; 93(7):1135-45. PubMed ID: 9657147
[TBL] [Abstract][Full Text] [Related]
25. Proteases involved in MHC class II antigen presentation.
Villadangos JA; Bryant RA; Deussing J; Driessen C; Lennon-Duménil AM; Riese RJ; Roth W; Saftig P; Shi GP; Chapman HA; Peters C; Ploegh HL
Immunol Rev; 1999 Dec; 172():109-20. PubMed ID: 10631941
[TBL] [Abstract][Full Text] [Related]
26. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.
Adams S; Humphreys RE
Eur J Immunol; 1995 Jun; 25(6):1693-702. PubMed ID: 7614997
[TBL] [Abstract][Full Text] [Related]
27. Lysosomal cysteine proteases and antigen presentation.
Rudensky A; Beers C
Ernst Schering Res Found Workshop; 2006; (56):81-95. PubMed ID: 16329647
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin S, but not cathepsin L, participates in the MHC class II-associated invariant chain processing in large yellow croaker (Larimichthys crocea).
Li Q; Ao J; Mu Y; Yang Z; Li T; Zhang X; Chen X
Fish Shellfish Immunol; 2015 Dec; 47(2):743-50. PubMed ID: 26475363
[TBL] [Abstract][Full Text] [Related]
29. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
[TBL] [Abstract][Full Text] [Related]
30. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
[TBL] [Abstract][Full Text] [Related]
31. Identification of a potent and selective noncovalent cathepsin S inhibitor.
Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
[TBL] [Abstract][Full Text] [Related]
32. Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing.
Moss CX; Villadangos JA; Watts C
Eur J Immunol; 2005 Dec; 35(12):3442-51. PubMed ID: 16259009
[TBL] [Abstract][Full Text] [Related]
33. Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption.
Katunuma N; Matsunaga Y; Matsui A; Kakegawa H; Endo K; Inubushi T; Saibara T; Ohba Y; Kakiuchi T
Adv Enzyme Regul; 1998; 38():235-51. PubMed ID: 9762356
[TBL] [Abstract][Full Text] [Related]
34. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs.
Bania J; Gatti E; Lelouard H; David A; Cappello F; Weber E; Camosseto V; Pierre P
Proc Natl Acad Sci U S A; 2003 May; 100(11):6664-9. PubMed ID: 12748383
[TBL] [Abstract][Full Text] [Related]
35. Redundancy between Cysteine Cathepsins in Murine Experimental Autoimmune Encephalomyelitis.
Allan ER; Yates RM
PLoS One; 2015; 10(6):e0128945. PubMed ID: 26075905
[TBL] [Abstract][Full Text] [Related]
36. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E.
Bennett K; Levine T; Ellis JS; Peanasky RJ; Samloff IM; Kay J; Chain BM
Eur J Immunol; 1992 Jun; 22(6):1519-24. PubMed ID: 1601038
[TBL] [Abstract][Full Text] [Related]
37. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
38. Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model.
Kubo K; Kawato Y; Nakamura K; Nakajima Y; Nakagawa TY; Hanaoka K; Oshima S; Fukahori H; Inami M; Morokata T; Higashi Y
Eur J Pharmacol; 2018 Nov; 838():145-152. PubMed ID: 30196110
[TBL] [Abstract][Full Text] [Related]
39. Destructive proteolysis by cysteine proteases in antigen presentation of ovalbumin.
Rodriguez GM; Diment S
Eur J Immunol; 1995 Jul; 25(7):1823-7. PubMed ID: 7621859
[TBL] [Abstract][Full Text] [Related]
40. Cathepsin S inhibitors as novel immunomodulators.
Thurmond RL; Sun S; Karlsson L; Edwards JP
Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
